Phytopharm
 | This article needs additional citations for verification. (April 2014) |
| Company type | Pharmaceutical |
|---|---|
| Defunct | 14 October 2013[1] |
| Headquarters | Huntingdon , United Kingdom |
Area served | Pharmaceuticals |
Phytopharm was a pharmaceutical company based in the United Kingdom. According to the company's website, its lead products were Cogane and Myogane, which are members of the sapogenin class of compounds. It was listed on the London Stock Exchange and was a constituent of the FTSE Fledgling Index.[citation needed]
The company collapsed following failure of its main drug during clinical trials.[2] It is now named Ixico.[3]
References
- ^ "Phytopharm shareholders approve IXICO acquisition". 14 October 2013. Retrieved 9 December 2014.
- ^ "Phytopharm says Cogane Phase II trials disappoint". 18 February 2013. Retrieved 9 December 2014.
- ^ http://www.londonstockexchange.com/exchange/prices-and-markets/stocks/new-and-recent-issues/new-recent-issue-details.html?issueId=8901
See also
External links
 | This article about a company of the UK is a stub. You can help Wikipedia by expanding it. |